12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Etirinotecan pegol regulatory update

Nektar said FDA granted Fast Track designation to etirinotecan pegol to treat locally recurrent or metastatic breast cancer...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >